Article

The impact of weight loss among seniors on Medicare spending

Health economics review 03/2013; 3(1):7. DOI: 10.1186/2191-1991-3-7
Source: PubMed

ABSTRACT

Objective
To examine the impact of temporary and permanent weight loss of 10% and 15% on 10-year and lifetime Medicare spending among adults with overweight and obesity aged 65 years and older. Weight loss of this magnitude is consistent with next generation anti-obesity medications recently approved by the Food and Drug Administration.

Methods
We follow the approach of a longitudinal dynamic aging process model developed by our research team. This model considers the dynamic relationships between weight, chronic disease, acute medical events, functional status, mortality, health care utilization and spending among Medicare beneficiaries from age 65 until death. Using this model, we estimate baseline Medicare spending over the next decade and then over the lifetime of seniors with a body mass index (BMI) ≥ 27 with at least one weight-related comorbidity (overweight), and seniors with obesity having a BMI ≥ 30 and ≥ 35. We then estimate Medicare spending for this population between ages 65 and 70 over the course of a year, assuming 10% and 15% weight loss under alternative scenarios: with and without weight regain. (Weight regain is assumed to be 90% over a 10-year period.) The difference in spending between baseline (no weight-loss intervention) and the alternative scenarios represent potential gross savings to the Medicare program.

Results
Permanent weight loss of 10 to 15% will yield $9,445 to $15,987 in gross per capita savings throughout their lifetime, and $8,070 to $13,474 over ten years. Similarly, initial weight loss of 10 to 15% followed by 90% weight regain will result in gross per capita savings of $7,556 to $11,109 over their lifetime, and $6,456 to $8,911 over ten years. Targeting weight loss medications to adults with obesity (BMI ≥ 30) produces greater savings to the Medicare program.

Conclusion
Medicare can realize significant cost savings through anti-obesity medications that produce substantial weight loss, and as a result, reduce the progression to type 2 diabetes, and improve blood pressure and glycemic indicators in hypertensive and diabetic patients, respectively. Medications are currently excluded from coverage in the Medicare program, however, in light of potential savings and health benefits, may warrant consideration.

Download full-text

Full-text

Available from: link.springer.com · License: CC BY
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity and its many serious comorbidities exert a heavy toll in both human and economic terms. More than one-third of adults in the United States are obese and, therefore, subject to elevated rates of diabetes, hypertension, dyslipidemia, and other cardiovascular disease risk factors. The negative effect on the quality of life (QoL) of these individuals is enormous. Among the severely obese, QoL scores are comparable to QoL scores associated with diabetes and laryngeal cancer. The medical costs of obesity-related illnesses in the United States have been estimated at $209.7 billion annually (in 2008 dollars). For example, with regard to impact on pharmaceutical costs, obesity is associated with a more than 13-fold increase in the cost of antidiabetic medications. The cost of absenteeism to employers has been estimated to exceed $4.3 billion annually. Successful and cost-effective short-term treatments for obesity are available, and have been shown to reduce cardiovascular risk factors. Intensive lifestyle intervention with the goal of losing 7% of baseline body weight, for example, resulted in a 58% reduction in the risk of diabetes in patients with prediabetes. In clinical trials, improvements in other cardiovascular risk factors, such as elevated triglycerides and high blood pressure, have also been seen with a modest weight loss of 5% to 10% of baseline body weight. As obesity becomes an ever greater public health problem, additional interventions with long-term efficacy are needed to reduce body weight and maintain weight loss.
    No preview · Article · Aug 2013 · The American journal of managed care
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Recent advances in lifestyle intervention programs, pharmacotherapy, and bariatric surgery have enabled the development of medical models for the treatment of obesity. Regarding pharmacotherapy, in 2012 the FDA approved two new effective and safe weight loss medications, phentermine/topiramate extended release and lorcaserin, which has greatly augmented options for medically-assisted weight loss.Methods: Rationale for advantages of a complications-centric medical model, over current BMI-centric indications for therapy, is examined.Results: Currently, the baseline BMI level is the principle determinant of indications for obesity treatment using medication and surgery. However, the BMI-centric approach fails to target therapy to those obese patients who will benefit most from weight loss. In contrast, a complications-centric medical model is proposed that will earmark the modality and intensity of the therapeutic intervention based on the presence and severity of complications that can be ameliorated by weight loss.Conclusion: The complications-centric approach to "medicalizing" obesity care employs weight loss primarily as a tool to treat obesity-related complications, and promotes the optimization of health outcomes, the benefit/risk, and the cost effectiveness of therapy.
    No preview · Article · Sep 2013 · Endocrine Practice
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoarthritis (OA) is the most common chronic condition and principal cause of disability among older adults. The current obesity epidemic has contributed to this high prevalence rate. Fortunately both OA symptoms and obesity can be ameliorated through lifestyle modifications. Physical activity (PA) combined with weight management improves physical function among obese persons with knee OA but evidence-based interventions that combine PA and weight management are limited for this population. This paper describes a comparative effectiveness trial testing an evidence-based PA program for adults with lower extremity (LE) OA, Fit and Strong!, against an enhanced version that also addresses weight management based on the evidence-based Obesity Reduction Black Intervention Trial (ORBIT). Adult participants (n=400) with LE OA, age 60+, overweight/obese, and not meeting PA requirements of>=150minutes per week, are randomized to one of the two programs. Both 8-week interventions meet 3 times per week and include 60minutes of strength, flexibility, and aerobic exercise instruction followed by 30minutes of education/group discussion. The Fit and Strong! education sessions focus on using PA to manage OA; whereas Fit and Strong! Plus addresses PA and weight loss management strategies. Maintenance of behavior change is reinforced in both groups during months 3 - 24 through telephone calls and mailed newsletters. Outcomes are assessed at baseline, and 2, 6, 12, 18, and 24months. Primary outcomes are dietary change at 2months followed by weight loss at 6months that is maintained at 24months. Secondary outcomes assess PA, physical performance, and anxiety/depression.
    Full-text · Article · Dec 2013 · Contemporary clinical trials
Show more